Israel is among the most expensive countries in the world for treating patients with dementia, with an average of $5,000 for a single day’s care and $2,000 a day for a couple.
But a few specialists who specialize in the care of those with Alzheimer’s disease have been finding a new way to get around the high cost.
“I’ve always been a proponent of the public service,” said Dr. Shai Shor, a neurologist in Jerusalem who specializes in the treatment of people with dementia.
“The idea of doing it in private, you have to get to the right people.”
Shor said that he had started treating people with Alzheimer to see how they coped.
“We are talking about a person who has cognitive impairment and is suffering from memory loss, and they are living in their home and are not able to interact with others,” he said.
“There are very few places for them to go to.”
Shorr said that some of his patients, who he called “people who were living in a coma, have no idea what they are doing and that they need a certain level of supervision.”
“It’s a completely different situation, the patient is living in the hospital, but the physician is in a private environment and can’t see them,” he added.
In Israel, there are roughly 8,000 dementia patients in hospitals, according to a recent survey.
There are roughly 2,000 private doctors and clinics in the country, but it’s unclear how many are offering services to people with mild dementia.
Shor works at a privately run facility in Israel that specializes in Alzheimer’s.
He said he has treated more than 50 patients with mild Alzheimer’s and that a few patients with moderate dementia and dementia have been able to access the services at his facility.
The main treatment is medication and physical therapy, but there are many other treatments.
“Our patients have to be very, very, careful with their medication because if you put too much in too little, it’s not going to help them,” Shor explained.
He and his colleagues at the Loma Linda Neurology and Neurobiology Center have also started working with people with chronic pain, which has been a major problem in the Middle East and South Asia, where people with the condition often live in poverty.
“It takes a long time for the doctor to understand this,” Shorr explained.
“A patient has to be on medication for six months before they are allowed to take the medication.
And if they don’t take the medications, the doctor doesn’t have the ability to treat the disease.”
Shrout said that the patients are being monitored very carefully to make sure they don,t take too much pain medication, but that the medications have to last for three to six months.
“If you do not take it for two or three weeks, then you have an accident and you die,” Shrouts said.
Some patients have also been able find private care in the United States, but those options have been limited because of the U.S. government’s strict regulations on care for the elderly.
Shorr says that his team has also found that people in Israel have also found ways to pay for the care.
“Some patients in Israel are living on $50,000, which is unbelievable,” Shoor said.
He explained that his facility charges $2.5 million for a patient who has mild dementia and that patients who require a special form of treatment that has a higher price tag are asked to pay another $300,000 to cover the cost.
He also said that a couple of patients who are having their dementia treated by a private hospital in Israel can be charged an extra $2 million to $3 million, depending on the type of care they need.
“One of them had a $2-million bill for a brain transplant,” Shruor said.
Dr. David Raffensberger, a neurosurgeon in Jerusalem and president of the Israeli Association for Neurological and Neurosurgical Care, said that while he thinks that private care can be an effective option, he is concerned about the stigma attached to the process.
“You are dealing with a person that has very serious dementia, who has a disability that requires constant attention,” he explained.
Raffersberger, who is also a member of the board of the American Association for the Advancement of Science, said he does not believe that private doctors can be trusted to treat people with cognitive impairment.
“They have a much greater burden than they should because of their age, because of what the person is doing, because they are a person of interest,” Raffansberger said.
In the United Kingdom, a private doctor is not required to have a license to practice neurology.
However, many countries in Europe and North America require a license for neurologists.